FDMT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FD

Mkt Cap

$670.9M

Volume

548.34K

Next Earnings

November 9th

Loading chart

FD

FDMT4D Molecular Therapeutics, Inc. Common Stock

FDMT

Pay with—

Available Balance0.00

FD

Mkt Cap

$711.0M

Volume

548.34K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

4DMT to Participate in Upcoming Investor Conferences4DMT announced management presentations at three major healthcare investor conferences in September 2026. The company reported completion of enrollment for its lead product 4D-150 Phase 3 trial (4FRONT-2) for wet AMD with topline data expected in H2 2027, and positive 2-year data from the 4D-150 PRISM trial. 4D-710, the company's genetic medicine for cystic fibrosis, continues development.GlobeNewswire Inc. · Aug 25, 2026

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population4D Molecular Therapeutics (4DMT) announced positive 2-year results from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD). The single-dose treatment demonstrated consistent maintenance of visual acuity and anatomic control with 78-87% reduction in treatment burden compared to standard aflibercept injections. The therapy was well-tolerated with no new safety concerns or intraocular inflammation cases beyond the first 6 months.GlobeNewswire Inc. · Jul 18, 2026

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.GlobeNewswire Inc. · Jun 29, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.GlobeNewswire Inc. · Jun 18, 2026

4DMT to Participate in Upcoming Investor Conferences4D Molecular Therapeutics (4DMT) announced that management will present at three major investor conferences in March 2026: TD Cowen Health Care Conference (March 3), Leerink Global Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 12). The company is advancing late-stage biotech therapeutics including 4D-150 for retinal vascular diseases currently in Phase 3 development and 4D-710 for cystic fibrosis.GlobeNewswire Inc. · Feb 19, 2026

4DMT Appoints Kristian Humer as Chief Financial Officer4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.GlobeNewswire Inc. · Nov 17, 2025

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.GlobeNewswire Inc. · Oct 31, 2025

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific OfficerGenVivo appointed Dr. Noriyuki Kasahara as Chief Scientific Officer to advance its genetic therapy platform for cancer treatment, leveraging his extensive experience in gene therapy and vector technology research.GlobeNewswire Inc. · Sep 11, 2025

4dMT Revenue Jumps 200 Percent in Q24D Molecular Therapeutics reported Q2 2025 financial results with $15 million revenue, exceeding estimates, driven by collaboration income. The company advanced its gene therapy programs for retinal and respiratory diseases, with promising clinical trial progress and a workforce reduction to manage expenses.The Motley Fool · Aug 11, 2025

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones4DMT reported Q2 2025 financial results, highlighting accelerated Phase 3 clinical trials for 4D-150 in wet AMD and DME, positive 60-week trial results, and a workforce reduction to drive late-stage execution with $417 million cash runway into 2028.GlobeNewswire Inc. · Aug 11, 2025

to start trading

FD

FDMT4D Molecular Therapeutics, Inc. Common Stock

FDMT

Pay with—

Available Balance0.00

Your PositionYou don't own any FDMT yet.

Related Tickers

Earnings